Trials / Recruiting
RecruitingNCT06318507
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (estimated)
- Sponsor
- Pennington Biomedical Research Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Fecal microbial diversity | Fecal microbiome diversity via 16S rRNA and metagenomic sequencing |
Timeline
- Start date
- 2024-03-11
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-03-19
- Last updated
- 2025-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06318507. Inclusion in this directory is not an endorsement.